Loading stock data…
STAAR Surgical Company (STAA)
$24.16+0.69 (+2.94%)
Market ClosedLast close Sep 8
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells phakic implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
STAAR Surgical Company in the Healthcare sector is trading at $24.16 with a market capitalization of $1.2B. Wall Street consensus targets $27.90 (10 analysts), implying a +15.5% move over the next 12 months. The stock is currently 33% below its 52-week high of $35.87, remaining 0.5% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +15.5% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $93.52M↑ | $57.80M↓ | $94.73M↑ | $44.32M↑ | $42.59M |
| Gross Profit | $68.86M↑ | $43.74M↓ | $77.88M↑ | $32.80M↑ | $28.00M |
| Operating Income | $17.40M↑ | -$10.94M↓ | $24.44M↑ | -$24.72M↑ | -$34.74M |
| Net Income | $5.21M↑ | -$18.31M↓ | $8.88M↑ | -$16.81M↑ | -$54.21M |
Peer Comparison
JNJUNHPFE
Fundamentals
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells phakic implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye. The company offers implantable collamer lens p...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.21B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
302.00
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.22
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
1.05%
Volume
Today's trading volume
1.40M
Recent News
1 Russell 2000 Stock for Long-Term Investors and 2 Facing Challenges
The Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on. However, these companies often come with higher volatility and risk, as their smaller size makes them more vulnerable to economic downturns.
1 Cash-Burning Stock to Keep an Eye On and 2 We Turn Down
While some companies burn cash to fuel expansion, others struggle to turn spending into sustainable growth. A high cash burn rate without a strong balance sheet can leave investors exposed to significant downside.
Stocks making big moves this week: Bally's, Adobe, Novavax, Semtech, and STAAR Surgical
Check out the companies making headlines this week:
STAAR (STAA) Q2 2026 Earnings Call Transcript
Record revenue and return to profitability driven by EVO Plus expansion in China.
5 Insightful Analyst Questions From STAAR Surgical’s Q2 Earnings Call
STAAR Surgical’s second quarter results surpassed Wall Street’s expectations for both revenue and adjusted earnings, but the market reacted negatively, likely reflecting investor caution about the sustainability of recent growth. Management attributed the strong quarter to increased adoption of EVO Plus in China, ongoing market share gains from laser-based competitors, and consistent double-digit growth outside China, especially in the U.S. and EMEA. CEO Warren Foust emphasized that the company’